Topical cyclosporin A in the management of vernal keratoconjunctivitis.
OBJECTIVE
To study the efficacy of topical cyclosporin A in children with vernal keratoconjunctivitis in a prospective randomised double-masked trial.


METHODS
Twenty-four children between 5 and 16 years of age were randomly treated with cyclosporin A (CsA) and placebo (vehicle) and followed up for 4 months.


RESULTS
Of the 12 patients given CsA, 11 showed symptomatic improvement by 7 days of starting treatment whereas only 3 patients in the placebo group showed mild symptomatic improvement.


CONCLUSIONS
Topical cyclosporin is a safe and effective treatment in vernal keratoconjunctivitis.
Gupta
V
V
Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi. gupta_v@mailcity.com
Sahu
P K
PK
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D016572:Cyclosporine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D009883:Ophthalmic Solutions; D016572:Cyclosporine